Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
07:30am, Tuesday, 26'th Aug 2025
HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platf
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
07:30am, Monday, 18'th Aug 2025
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting tox
Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
07:30am, Friday, 15'th Aug 2025
HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics wi
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
06:31pm, Thursday, 14'th Aug 2025
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.71 per share a year ago.
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
04:15pm, Thursday, 14'th Aug 2025
Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeu
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
07:30am, Thursday, 14'th Aug 2025
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
07:30am, Thursday, 31'st Jul 2025
CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden r
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
07:30am, Wednesday, 23'rd Jul 2025
Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development program Payment is part of $17.6 million award granted for leptomeningeal cancer targeted
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
07:30am, Tuesday, 15'th Jul 2025
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Le
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
07:30am, Thursday, 10'th Jul 2025
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases
Substantial clinical need expected to facilitate rapid overall trial enrollment Substantial clinical need expected to facilitate rapid overall trial enrollment
Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from t
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
07:30am, Thursday, 26'th Jun 2025
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a co
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
04:15pm, Wednesday, 25'th Jun 2025
HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced plat
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025 (GLOBE
